Dupont Capital Management Corp Allogene Therapeutics, Inc. Transaction History

Dupont Capital Management Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 31, 2022	SELL	$10.32 - $17.28 $45,944 - $76,930	-4,452 Reduced 28.15%	11,365 $123,000
Q1 2022 Apr 27, 2022	SELL	$7.65 - $15.29 $10,702 - $21,390	-1,399 Reduced 8.13%	15,817 $144,000
Q4 2021 Jan 31, 2022	BUY	$13.13 - $24.52 $72,582 - $135,546	5,528 Added 47.3%	17,216 $257,000
Q3 2021 Nov 03, 2021	SELL	$21.01 - $27.64 $34,729 - $45,688	-1,653 Reduced 12.39%	11,688 $300,000
Q2 2021 Jul 30, 2021	BUY	$23.49 - $35.8 $313,380 - $477,607	13,341 New	13,341 $348,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.